A field of Ozempic at a pharmacy in Los Angeles on Aug. 6, 2025.
Eric Thayer/Bloomberg through Getty Photos
conceal caption
toggle caption
Eric Thayer/Bloomberg through Getty Photos
The federal authorities has introduced the outcomes of the newest spherical of Medicare drug worth negotiations: 15 decrease drug costs for Medicare to enter impact in 2027.
Medicare will get a 71% low cost on Ozempic, Wegovy and Rybelsus, blockbuster medicine for weight problems and Sort 2 diabetes which have present checklist costs of round a thousand {dollars} a month.
The negotiations additionally included medicine for bronchial asthma, breast most cancers and leukemia. The reductions ranged from 38% for Austedo, which treats Huntington’s illness, to 85% for Janumet for Sort 2 diabetes.
“President Trump directed us to cease at nothing to decrease well being care prices for the American individuals,” mentioned Well being and Human Providers Secretary Robert F. Kennedy, Jr., in a press launch. “As we work to Make America Wholesome Once more, we are going to use each instrument at our disposal to ship reasonably priced well being care to seniors.”
This system that covers medicine for greater than 50 million seniors negotiated its first batch of drug costs final yr, after the passage of the Biden-era Inflation Discount Act in 2022.
A provision of that legislation, handed with out Republican help, ended Medicare’s 20-year ban on negotiating drug costs.
Negotiations for this second batch of 15 medicine wrapped up on the finish of October.
The Facilities for Medicare and Medicaid Providers (CMS) say the brand new, decrease Medicare costs would have saved this system $12 billion {dollars} if the decrease negotiated costs had been in impact in 2024.
The most recent negotiated costs are nice information for taxpayers and sufferers, says Dr. Benjamin Rome, well being coverage researcher at Brigham and Girls’s Hospital in Boston. Federal taxpayers fund a lot of Medicare, however beneficiaries additionally should pay copays and coinsurance.
“That is extra financial savings than the primary spherical, however a variety of that has to do with the character of the medicine being negotiated this yr and possibly some studying from expertise,” he says.
Medication have been chosen earlier this yr primarily based on standards written into the legislation. They needed to haven’t any generic or biosimilar competitors, account for a excessive quantity of Medicare spending and be in the marketplace for various years.
The decrease Ozempic and Wegovy costs observe a separate deal the Trump administration introduced on Nov. 6 with Novo Nordisk, which makes each medicine.
That deal was a part of the president’s push to get drug firms to voluntarily decrease their U.S. costs to match these in different developed nations.
However, confusingly, the reductions from the Medicare negotiations have been much less vital than what Novo Nordisk agreed to offer Medicare as a part of the Nov. 6 deal.
That earlier deal set a worth of $245 {dollars} a month for Ozempic and Wegovy. However in line with the negotiated costs introduced this week, the costs of Ozempic, Wegovy and Rybelsus — the corporate’s Sort 2 diabetes tablet — might be $274 a month.
“It isn’t clear why Novo (Nordisk) would promise a special worth in two completely different venues,” Rome says.
In an organization assertion, Novo Nordisk defined that it “look(s) ahead to further readability from CMS on how pricing and protection will work.”
The separate Trump Administration deal “displays a broader effort to broaden entry to weight problems care throughout Medicare and Medicaid,” the assertion mentioned.
(The deal expanded entry in these two applications to the medicine to individuals with a physique mass index of over 35 and other people with BMIs above 27 who’ve further well being circumstances. However the particulars of precisely how it will work stay unclear.)
The Novo Nordisk assertion affirmed that the corporate is dedicated to advocating for reasonably priced entry to its medicines, however “we proceed to have severe considerations in regards to the Inflation Discount Act’s influence on sufferers and stay against authorities worth setting.”
AARP, an advocacy group for the 125 million Individuals who’re 50 and older, was happy with the outcomes of the negotiations.
“Immediately’s announcement marks yet one more vital subsequent step ahead in our long-standing efforts to decrease prescription drug costs,” AARP’s CEO Dr. Myechia Minter-Jordan mentioned in a press release.
“Older Individuals throughout the political spectrum persistently say decrease drug costs are a high precedence, and these negotiated costs will deliver significant reduction to tens of millions of individuals on Medicare.”
